Latest News
COMP360 Approval: When Could Compass’s Psilocybin Be Cleared?
No COMP360 approval date exists yet, but the timetable is short. Compass Pathways said its rolling new drug application (NDA) should finish “in the next two weeks”. It made the statement on 3 November 2026, in its third-quarter 2026 results release. The company...
Latest News
OOS Investigation: A Solubility-Related HPLC Assay Failure
A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...
Pharma’s Digital Maturity Divide Is Holding Back AI Adoption
AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...
UK Biotech Venture Capital Nears a Record Year as Seed Funding Shrinks
UK biotech venture capital reached £2.84 billion in the first nine months of 2026. That is more than in any full year from 2022 to 2025. The figures come from the BioIndustry Association (BIA) Q3 2026 financing report, published on 26 October 2026 [1]. The BIA puts...
Connecting ADME and Mouse Models in Preclinical Oncology
In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Why Digital Therapeutics Struggle to Enter Clinical Workflows
The practical barriers between promising digital therapeutic research and routine care, from validation and safety reporting to staff adoption and patient experience. A digital therapeutic can produce encouraging research results, receive regulatory clearance and...
Weekly News Roundup | 28 September 2026
Life science news 28 September 2026: four US drug approvals, three UK developments and two global R&D deals. The FDA approved Atebrioz, the third treatment for fibrodysplasia ossificans progressiva, and AbbVie’s Parkinson’s drug Juvmo. The MHRA approved...
Multi-Cancer Early Detection Test Divides FDA Advisers
A United States advisory panel has recommended approval of a multi-cancer early detection blood test. The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee met on 23 September 2026. It reviewed GRAIL’s Galleri test. The assay reads...
Merck Wnt Agonist Meets Diabetic Macular Oedema Treatment Goal
Merck said on 24 September 2026 that remigromig met the primary endpoint of the pivotal Phase 2b/3 BRUNELLO study. Merck is known as MSD outside the United States and Canada. It said no new diabetic macular oedema treatment mechanism had matched anti-VEGF therapy in...
Online Prescribing Is Moving Faster Than Regulation
Online prescribing has moved from being a relatively niche part of healthcare to an increasingly established route through which patients access treatment. That change brings clear benefits. Patients can seek treatment discreetly, access clinicians without travelling,...
Clinical Trials Roundup | 25 September 2026
The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis. Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key...
Rethinking the Office: The Need for Healthier Buildings
For property owners, management companies, and business leaders, few sights are more unwelcome than an empty office building. Indoor air quality may be part of the answer to filling it. In the post-pandemic era, the home office has replaced the traditional workplace...
When Life Sciences Compliance Problems Are Really Operations Problems
When a life sciences organization struggles during a regulatory inspection or quality audit, the first reaction is fairly predictable: people point to evolving regulatory expectations, expanding documentation requirements, or the complexity of maintaining compliance...
Obesity Drug Access in the UK: NHS and Private Routes in 2026
Obesity drug access in the UK now runs along two tracks that rarely meet. One is a publicly funded NHS rollout of tirzepatide (Mounjaro), phased over as long as 12 years. The other is a private market that has grown far faster. A UCL survey estimates that about 1.6...
Transfusion Medicine in 2026: from Hemovigilance to Bedside Precision
Transfusion medicine plays a crucial role in modern healthcare by ensuring the availability of safe and compatible blood products for patients in need. Recognized globally as an essential medicine, blood remains the cornerstone of the healthcare workflow. Every few...
Surgical Site Infections Can Consume Up to 75 Staff Hours
Surgical site infections can consume up to 75 staff hours and displace three operations, research finds A single surgical site infection (SSI) can consume an estimated 45 to 75 additional hours of healthcare staff time and create downstream demands equivalent to the...
Amylin Analogues Explained: The Next Obesity Drug Battleground
Amylin analogues have become one of the most active areas of obesity drug development. Novo Nordisk, Eli Lilly, Roche, Pfizer, AbbVie and AstraZeneca all hold clinical programmes built on the hormone amylin. The most advanced obesity candidate in the class, Novo...
Why Digital Therapeutics Struggle to Enter Clinical Workflows
The practical barriers between promising digital therapeutic research and routine care, from validation and safety reporting to staff adoption and patient experience. A digital therapeutic can produce encouraging research results, receive regulatory clearance and...
Weekly News Roundup | 28 September 2026
Life science news 28 September 2026: four US drug approvals, three UK developments and two global R&D deals. The FDA approved Atebrioz, the third treatment for fibrodysplasia ossificans progressiva, and AbbVie’s Parkinson’s drug Juvmo. The MHRA approved...
Multi-Cancer Early Detection Test Divides FDA Advisers
A United States advisory panel has recommended approval of a multi-cancer early detection blood test. The Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee met on 23 September 2026. It reviewed GRAIL’s Galleri test. The assay reads...
Merck Wnt Agonist Meets Diabetic Macular Oedema Treatment Goal
Merck said on 24 September 2026 that remigromig met the primary endpoint of the pivotal Phase 2b/3 BRUNELLO study. Merck is known as MSD outside the United States and Canada. It said no new diabetic macular oedema treatment mechanism had matched anti-VEGF therapy in...
Online Prescribing Is Moving Faster Than Regulation
Online prescribing has moved from being a relatively niche part of healthcare to an increasingly established route through which patients access treatment. That change brings clear benefits. Patients can seek treatment discreetly, access clinicians without travelling,...
Clinical Trials Roundup | 25 September 2026
The clinical trial results 25 September 2026 span Sjögren’s, urticaria, IgA nephropathy, obesity, cutaneous lupus and Alzheimer’s psychosis. Amgen’s dazodalibep met its primary endpoint in systemic Sjögren’s disease. Celldex’s barzolvolimab met its primary and all key...
Rethinking the Office: The Need for Healthier Buildings
For property owners, management companies, and business leaders, few sights are more unwelcome than an empty office building. Indoor air quality may be part of the answer to filling it. In the post-pandemic era, the home office has replaced the traditional workplace...
When Life Sciences Compliance Problems Are Really Operations Problems
When a life sciences organization struggles during a regulatory inspection or quality audit, the first reaction is fairly predictable: people point to evolving regulatory expectations, expanding documentation requirements, or the complexity of maintaining compliance...
Obesity Drug Access in the UK: NHS and Private Routes in 2026
Obesity drug access in the UK now runs along two tracks that rarely meet. One is a publicly funded NHS rollout of tirzepatide (Mounjaro), phased over as long as 12 years. The other is a private market that has grown far faster. A UCL survey estimates that about 1.6...
Transfusion Medicine in 2026: from Hemovigilance to Bedside Precision
Transfusion medicine plays a crucial role in modern healthcare by ensuring the availability of safe and compatible blood products for patients in need. Recognized globally as an essential medicine, blood remains the cornerstone of the healthcare workflow. Every few...
Surgical Site Infections Can Consume Up to 75 Staff Hours
Surgical site infections can consume up to 75 staff hours and displace three operations, research finds A single surgical site infection (SSI) can consume an estimated 45 to 75 additional hours of healthcare staff time and create downstream demands equivalent to the...
Amylin Analogues Explained: The Next Obesity Drug Battleground
Amylin analogues have become one of the most active areas of obesity drug development. Novo Nordisk, Eli Lilly, Roche, Pfizer, AbbVie and AstraZeneca all hold clinical programmes built on the hormone amylin. The most advanced obesity candidate in the class, Novo...
Featured Articles
Further News
The New Launch Model for the Agentic Era
Creating brand value when clinical information is no longer a differentiator The Life Sciences industry is undergoing seismic shifts: expanding drug pipelines, compressed launch timelines, and changing healthcare provider (HCP) and human capital expectations. HCPs...
Britain’s Nicotine Pouch Problem: What It Means for Oral Health
The UK Government has taken steps to combat smoking, and now nicotine pouches, through legislation, public health campaigns, youth prevention and support services. In the UK the age limit for smoking is 18 years old, meaning that individuals must be at least 18 to buy...
FUS-ALS Treatment Clears Phase 3 but the Figures Stay Unpublished
Ionis Pharmaceuticals and Otsuka Pharmaceutical reported positive topline results on 22 September 2026 from the Phase 3 FUSION study. The trial tested ulefnersen in amyotrophic lateral sclerosis caused by mutations in the fused in sarcoma gene. Ionis describes the...
Why Business Fundamentals Belong in Every Life Sciences Career
As a life scientist you might not have considered a business education. You are good at what you do, you may have no ambition to run a company or sit at a boardroom table. So why spend time on business fundamentals? The honest answer is that deep technical expertise...
Telix Buys ITM: Radioisotope Supply and a Manufacturing Test
Telix Pharmaceuticals has agreed to buy ITM Isotope Technologies Munich SE. Telix describes ITM as the largest supplier of lutetium-177 by revenue. The deal places that radioisotope supply business inside a therapeutics developer. Telix issued the joint announcement...
LNP Engineering for RNA Delivery: Beyond Encapsulation Efficiency
For RNA therapeutics, encapsulation efficiency is a formulation metric—not proof of functional delivery. The development of lipid nanoparticle (LNP) RNA delivery systems is entering a more demanding phase. As nucleic acid therapeutics expand beyond conventional siRNA...
Closing the Gap: Why Where You Live Still Determines Your IBD Care
Inflammatory bowel disease (IBD) is no longer a rare disease in Australia. Close to 180,000 Australians are now living with Crohn’s disease or ulcerative colitis, with prevalence approaching 1% of the population in some estimates. Unlike many chronic diseases, IBD...
How GLP-1 Drugs Are Reshaping Anesthesia Practice
Few classes of medications have changed the perioperative conversation as quickly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Originally developed primarily for the management of type 2 diabetes, GLP-1 therapy is now widely used for obesity and metabolic...
Designing Resilient Health Systems That Endure
The most resilient health systems are not the ones that respond best in times of disruption, they’re the ones designed so that when disruption occurs, care continues and communities remain protected. Systems continue to struggle with workforce shortages, delayed care,...
Weekly News Roundup | 21 September 2026
Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation. The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer...
Vivan Therapeutics and Ad Atomica Announce Discovery Collaboration
Partnership pairs Vivan's genotype resolved cancer screening data with Ad Atomica's AI driven molecule design platform LONDON, UK, 16 September 2026: Vivan Therapeutics and Ad Atomica today announced a discovery collaboration. Vivan tests thousands of drugs and drug...
Azetukalner NDA Filed as Xenon Pauses Depression Trials
Xenon Pharmaceuticals submitted the azetukalner NDA to the US Food and Drug Administration on 17 September 2026. The filing covers focal seizures in epilepsy. The same announcement disclosed a voluntary pause on new enrolment in the company’s depression studies. Xenon...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.